CIK 0001840233 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Xilio Therapeutics, Inc.
Sign in to watch- Ticker
- XLO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851623397
- Phone
- 617-833-1027
- Business address
- 828 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −300,000 | 0 | ||
| 2025-11-21 | Frankenfield Christopher James Chief Financial Officer | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +2,075,000 | 2,075,000 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Returned to the company · Stock Option (right to buy) | −239,703 | 0 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +239,703 | 239,703 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Returned to the company · Stock Option (right to buy) | −473,334 | 0 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +473,334 | 473,334 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Returned to the company · Stock Option (right to buy) | −135,134 | 0 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +135,134 | 135,134 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Returned to the company · Stock Option (right to buy) | −50,041 | 0 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +50,041 | 50,041 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Returned to the company · Stock Option (right to buy) | −100,000 | 0 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Returned to the company · Stock Option (right to buy) | −150,000 | 0 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Returned to the company · Stock Option (right to buy) | −350,000 | 0 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +350,000 | 350,000 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Returned to the company · Stock Option (right to buy) | −700,000 | 0 | ||
| 2025-11-21 | Russo Rene PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +700,000 | 700,000 | ||
| 2025-06-17 | Shannon James Samuel Director | Purchase | +25,000 | $0.69 | $17K | 70,000 |
Page 4 of 12 · 224 trades